Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

YM-53601

YM-53601 Structure
  • ₹0
  • Product name: YM-53601
  • CAS: 182959-33-7
  • MF: C21H21FN2O.ClH
  • MW: 372.869
  • EINECS:
  • MDL Number:MFCD06411577
  • Synonyms:2-[(2E)-2-(1-azabicyclo[2.2.2]octan-3-ylidene)-2-fluoroethoxy]-9H-carbazole:hydrochloride;2-[(2E)-2-(1-azabicyclo[2.2.2]oct-3-ylidene)-2-fluoroethoxy]-9H-carbazole, monohydrochloride;YM-53601 Exclusive;9H-Carbazole, 2-[(2E)-2-(1-azabicyclo[2.2.2]oct-3-ylidene)-2-fluoroethoxy]-, hydrochloride (1:1)
Manufacturer Product number Product description Packaging Price Updated Buy

Properties

Melting point :236.5-237.2 °C
storage temp. :Store at -20°C
solubility :DMF: 20 mg/ml; DMSO: 20 mg/ml; DMSO:PBS(pH 7.2) (1:3): 0.25 mg/ml; Ethanol: 2 mg/ml
form :A crystalline solid
color :Off-white to light brown

Safety Information

Symbol(GHS):
Signal word:
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
Precautionary statements:

Description

Squalene synthase catalyzes the dimerization of two farnesyl pyrophosphate molecules to form the key cholesterol precursor, squalene. YM-53601 inhibits squalene synthase activity in rat hepatic microsomes and human Hep-G2 cells with IC50 values of 90 and 79 nM, respectively. Cholesterol biosynthesis is inhibited in rats with an ED50 value of 32 mg/kg YM-53601, causing a reduction in both cholesterol and triglyceride levels in plasma. Cholesterol-reducing HMG-CoA reductase inhibitors, which have little effect on plasma triglyceride levels, are often paired with fibrates, which can have adverse effects, to treat hyperlipidemia. The lipid-lowering properties of compounds such as YM-53601 make squalene synthase inhibition an attractive alternative to the combination HMG-CoA reductase inhibitor/fibrate therapy.

Related product price